查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848840

肠道疾病检测市场按检测方法、产品类型、最终用户、病原体、检体类型和分销管道划分－全球预测，2025-2032年

Enteric Disease Testing Market by Test Method, Product Type, End User, Pathogen, Sample Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肠道疾病检测市场将成长至 70.5 亿美元，复合年增长率为 5.64%。

关键市场统计数据
基准年 2024 45.4亿美元
预计年份：2025年 48亿美元
预测年份 2032 70.5亿美元
复合年增长率 (%) 5.64%

全面了解不断发展的肠道疾病检测领域，其中技术、法规和临床需求共同塑造了诊断策略。

肠道疾病检测处于临床紧迫性和技术创新交汇点，其驱动力在于快速检测和应对细菌、病毒和寄生虫爆发的迫切需求。诊断实验室、医院、研究机构和学术中心依赖日益多样化的套件，包括生物化学检验、培养方法、免疫检测、分子诊断和定序技术。同时，不断发展的法律规范、不断变化的医保环境以及患者就医路径也在重塑检测方法的验证、应用和整合到常规工作流程中的方式。

当今的检测生态系统兼顾了选择性和非选择性培养等传统方法与即时聚合酵素链锁反应）和次世代定序等现代技术。在这种混合环境中，实验室管理者和临床负责人必须权衡通量、灵敏度、週转时间和拥有成本之间的优缺点。因此，采购决策不再是简单地用一种技术取代另一种技术，而是更专注于建立互补的诊断路径，以优化患者照护和监测能力。

此外，多重检测、快速侧向层析技术和数据分析软体的普及，正在扩大肠道检测的应用范围。因此，各机构必须克服采购的复杂性、培训需求和资料管理方面的挑战，同时也要维持诊断品质并遵守认证标准。本文将探讨一个科学严谨性与营运实用性结合的市场，以及策略选择如何决定机构抵御下一波肠道疾病威胁的能力。

技术融合和营运现代化将如何重塑诊断方式，并提升临床和公共卫生领域的病原体检测能力？

随着技术的成熟、工作流程的整合以及人们对监测期望的不断提高，肠道疾病检测的模式正在改变。分子诊断正从小众研究应用转向第一线临床工具，聚合酵素链锁反应）变异、恒温环型核酸扩增）和即时PCR能够更快、更灵敏地检测细菌、病毒和寄生虫标靶。同时，包括次世代定序仪和桑格定序在内的定序平台正被整合用于病原体鑑定、疫情追踪和抗菌药物抗药性分析，从而增强了数据分析和生物资讯学在常规临床实践中的作用。

同时，免疫检测方法也日趋多样化，化学化学冷光检测法、酵素结合免疫吸附试验和侧向层析免疫分析等技术的出现，拓展了照护现场和实验室检测的选择范围。虽然培养仍然是分离株回收和药敏试验的关键步骤，但越来越多的实验室正在将培养与快速分子检测相结合，以加快病例管理。仪器自动化和整合耗材系统的兴起减轻了人工操作负担，软体和维护服务也逐渐成为采购讨论的核心内容。

这种技术变革也体现在营运和市场动态中。包括诊断实验室、医院、研究机构和学术中心在内的终端使用者正在调整工作流程，以适应多重检测和高通量定序。分销管道也在相应调整，直销、分销商和线上平台各自在满足需求方面发挥不同的作用。这些变化正在重新定义公共卫生机构和临床医务人员检测、报告和应对肠道威胁的方式。

评估2025年关税调整如何重塑诊断相关人员的采购惯例、供应链弹性策略和资本规划。

2025年关税的实施和调整为肠道疾病检测的采购和供应链规划带来了新的复杂性。影响进口耗材、仪器和某些检测设备的关税调整迫使製造商和经销商重新评估筹资策略、调整定价模式并优化库存缓衝，以维持检测服务的连续性。这些措施对采购週期、资本投资计画以及国产产品与进口产品的相对竞争力都产生了连锁反应。

依赖专用试剂、套件和定序耗材的实验室被迫寻找替代供应商或协商长期供应协议，以减轻成本波动的影响。仪器製造商则透过重新设计材料清单、尽可能实现部分生产流程本地化以及提升服务水准来应对新关税环境下的整体拥有成本。此外，经销商也拓展了物流路线并整合货运，以更有效地控製到岸成本。

关税也影响了终端用户在进行资本投资时的策略考量。医院和参考实验室权衡了租赁和购买设备的利弊，一些机构为了避免短期成本上涨，在关税生效前加快了采购速度。同时，软体和维护服务领域的机构也开始着重挖掘现有资产的更多价值，而不是立即升级硬体。总体而言，关税的累积影响凸显了供应链韧性、供应商多元化和基于价值的采购在维持肠道检测能力方面的重要性。

基于深度细分的洞察揭示了检测方法、产品、最终用户需求和病原体优先顺序之间的交集，从而指导策略投资。

了解市场区隔动态对于使产品开发和上市策略与使用者需求保持一致至关重要，这涵盖了检测方法、产品类型、最终用户、病原体、样本类型和分销管道等各个方面。检测方法包括传统的生化检测（包括自动化和手动检测）、培养技术（包括非选择性和选择性培养基）以及免疫检测（例如化学冷光、酵素结合免疫吸附和侧向流动免疫分析）。分子诊断透过恒温环型核酸扩增、常规PCR和即时PCR平台提案明确的价值主张，而从Sanger测序到次世代定序等定序技术则支持对病原体进行深入的表征和监测。

在产品方面，套件和试剂等耗材是日常运作的核心，而免疫分析仪、PCR仪和定序仪等仪器则是决定通量和产能的资本投资。与之配套的是软体和服务，特别是数据分析工具和维护程序，它们能够延长仪器的运作，并将原始输出转化为可执行的洞察。最终用户涵盖学术和临床实验室、诊断参考中心、医院和研究机构，每个用户都有各自的采购週期、监管要求和性能预期。

曲状桿菌、大肠桿菌和沙门氏菌等细菌病原体需要培养和分子检测双重确认；腺病毒、诺罗病毒和轮状病毒等病毒病原体则需要采用高灵敏度的分子检测和免疫检测；而寄生虫则需要专门的样本处理通讯协定。血液、直肠拭子和粪便等样本类型对上游处理和核酸萃取都有不同的要求，这些都会影响检测方法的选择和工作流程的设计。此外，分销管道（包括直销、分销商和线上平台）会影响前置作业时间、服务水准和客户参与模式。将这些细分市场进行对比分析，可以揭示整合解决方案、捆绑式耗材和仪器服务以及针对性产品改进如何释放临床和营运价值。

区域间的差异化动态驱动诊断技术的差异化应用，影响采购路径，并塑造供应链韧性策略。

区域动态对美洲、中东和非洲以及亚太地区的采用模式、监管路径和供应链结构有显着影响。在美洲，临床实验室和医院系统通常优先考虑快速分子诊断和高通量设备，以应对大量患者和支持疫情爆发，而监管核准和报销机制则决定新检测方法的采用速度。该地区的实验室网路也在投资测序能力以用于监测，这推动了对耗材和生物资讯解决方案的需求。

在中东和非洲地区，法规环境的多样性和医疗基础设施的差异化，为集中式参考实验室和分散式检查模式创造了不同的发展机会。在许多国家，严格的验证要求凸显了认证试剂和认可工作流程的重要性，而公共卫生优先事项则推动了对能够整合多重检测和监测数据的平台进行投资。分销策略必须考虑到跨多个司法管辖区的复杂物流以及不同的采购惯例。

亚太地区拥有高度都市化的中心和快速发展的实验室市场，这共同催生了对尖端定序和可扩展免疫检测平台的需求。在一些国家，本地製造地影响供应链的韧性和成本结构，而与区域经销商的合作则能加速市场进入。在整个亚太地区，公私合作倡议、跨境监测计画和区域采购架构正日益影响肠道微生物组检测资源的分配和部署方式。

市场参与企业如何透过整合产品、策略伙伴关係和以数据为中心的服务来实现差异化，从而获得持续的临床应用？

肠道检测产业的龙头企业正致力于开发整合仪器、耗材和数位化服务的整合解决方案，以提高客户维繫和生命週期价值。拥有成熟免疫测量和分子生物学产品组合的公司正投资于自动化和互联互通，以缩短週转时间并提高结果的可重复性；而测序服务提供者则在推进文库製备试剂套件和简化生物资讯流程，以降低技术应用门槛。规模较小的创新企业则专注于快速照护现场横向流动化验、等温扩增试剂套件以及针对难培养标靶的专用培养基等细分领域。

策略活动包括透过伙伴关係拓展通路、共同开发契约加速检测方法检验，以及加强售后服务以提高设备运作和客户满意度。一些公司正专注于采用混合市场推广模式，将直接交易与通路伙伴关係结合，以满足日益多元化的终端用户偏好。我们还观察到一种新兴趋势，即基于订阅和服务的产品模式，将耗材与仪器和软体捆绑销售，从而简化收入来源并加深客户关係。

竞争优势日益取决于数据能力，包括与实验室资讯系统的互通性、强大的数据分析软体以及将复杂的测序结果转化为临床相关资讯的服务。随着相关人员将快速诊断、扩充性和可操作性洞察置于优先地位，能够提供端到端解决方案并展现可衡量营运效益的公司更有可能获得更强大的市场地位。

製造商和医疗系统可以采取哪些策略行动来增强韧性、加速产品推广应用并获得可衡量的营运和临床效益

产业领导者应采取果断行动，加强供应链建设，加速数位整合，并使产品系列与终端用户的实际工作流程相契合。首先，供应商多元化和建立紧急库存策略可以降低贸易中断和关税波动带来的风险。其次，投资于仪器、实验室资讯系统和分析平台之间的无缝数据连接，将提高营运效率，并增强高成本仪器的价值提案。

第三，製造商和经销商应考虑采用模组化商业模式，将耗材、仪器和软体服务整合到订阅计画中。这种模式可以降低资源有限的实验室的进入门槛，同时提供可预测的收入来源。第四，优先开发兼顾灵敏度、週转时间和易用性的检测方法，特别是针对常见肠道病原体（如曲状桿菌、大肠桿菌、沙门氏菌、诺罗病毒和轮状病毒）的检测方法，可以满足临床和公共卫生需求。第五，有针对性地投资于培训、技术支援和维护服务，可以确保设备运作并提高客户满意度，尤其是在检测能力参差不齐的地区。

最后，加强与学术中心、公共卫生机构和医院网路的合作，将有助于共同开发和检验以监测为重点的解决方案。透过实施这些措施，产业领导者可以增强韧性，加速创新诊断技术的应用，并在临床和实验室环境中带来可衡量的效益。

严谨的混合方法研究框架，整合了相关人员访谈、技术文献综述和跨来源三角验证，以确保获得可靠的见解。

本分析采用的调查方法结合了定性和定量方法，旨在全面了解肠道疾病检测的动态变化。主要研究包括对实验室主任、临床微生物学家、采购人员和产品经理进行结构化访谈，以了解实际营运中的限制因素、推广应用的驱动因素和技术偏好。此外，还与分销合作伙伴和服务机构进行了补充讨论，以了解物流、价格压力和售后服务支援模式等方面的背景资讯。

次要研究包括对监管指南、临床实践标准和近期同行评审文献的系统性回顾，以确认其与检验的测试程序和预期诊断效能的一致性。此外，还分析了产品文献、製造商技术规格和设备维修手册，以评估其吞吐量特性、耗材依赖性和整合能力。透过对不同测试方法、产品类型和最终用户类型的比较分析，识别出反覆出现的主题、能力差距和商业化路径。

数据综合分析强调资讯来源的三角验证，以协调不同相关人员的观点并减少偏见。在整个过程中，我们关注可重复性、资料来源的透明度以及研究结果对临床实验室、医院、研究机构和学术中心的相关性。这种混合方法既能提供可靠且可操作的见解，又能充分考虑肠道疾病检测中存在的操作异质性。

整合技术、营运和策略主题，重点阐述如何实现快速、可靠的肠道疾病诊断，以满足临床和公共卫生需求。

肠道疾病检测领域的特点是技术快速发展、操作复杂以及市场压力不断变化，这些因素共同要求相关人员制定清晰的策略。传统方法在病原体分离和抗药性分析中仍然发挥关键作用，而分子和定序技术已成为及时检测和流行病学调查的必要手段。耗材、仪器、软体和服务如今构成了一个相互依存的生态系统，其中一个领域的决策会影响其他领域的绩效和价值实现。

区域差异、关税主导的采购调整以及对稳健分销策略的需求，凸显了灵活的商业模式和强大的售后服务能力的重要性。从集中式参考实验室到即时侦测点，终端使用者需要量身订製的解决方案，这些方案需考虑样本类型、目标病原体和通量需求。能够提供整合式、数据驱动型解决方案并投资于伙伴关係和本地支援体系的公司，将更有能力满足这些多样化的需求。

展望未来，该行业的发展轨迹将受到检测化学、自动化和生物资讯学领域持续创新以及构建供应链韧性和监管一致性的共同努力的影响，从而形成更快速的诊断基础设施，更好地支持临床决策和肠道疾病的公共卫生监测。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩展多重分子检测范围，同时检测多种肠道病原体，可缩短诊断时间
  • 采用快速照护现场免疫检测进行以地区为基础诺罗病毒和轮状病毒感染疾病检测
  • 将次世代定序整合到临床环境中，以实现全面的疫情源头追踪和抗菌素抗药性分析
  • 推出基于 CRISPR 技术的粪便样本中微量肠道病原体超灵敏检测诊断平台
  • 诊断设备製造商与远端医疗提供者建立策略伙伴关係，以促进远距会诊和咨询。
  • 在公共卫生监测中，将数位化粪便诊断与人工智慧分析相结合，用于肠道疾病爆发的预测建模。
  • 用于可携式多重检测细菌、病毒和寄生虫肠道病原体的实验室晶片设备的监管核准和商业化
  • 粪便微生物组检测作为胃肠道感染疾病鑑别诊断和个人化治疗的辅助工具，需求日益增长

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依检测方法分類的肠道疾病检测市场

  • 生物化学检验
    • 自动生化分析
    • 手动生物化学检验
  • 培养方法
    • 非选择性培养
    • 选择性培养
  • 免疫检测
    • 化学冷光免疫检测
    • 酵素结合免疫吸附试验
    • 横向流动化验
  • 分子诊断
    • 环介导等温扩增
    • 聚合酵素链锁反应
    • 即时聚合酵素链锁反应
  • 定序
    • 次世代定序
    • 桑格定序

9. 肠道疾病检测市场（依产品类型划分）

  • 消耗品
    • 套件
    • 试剂
  • 仪器
    • 免疫分析仪
    • 聚合酵素链锁反应装置
    • 序列器
  • 软体和服务
    • 数据分析软体
    • 维护服务

第十章 依最终用户分類的肠道疾病检测市场

  • 学术和临床研究实验室
  • 诊断实验室
  • 医院
  • 研究所

11. 按病原体分類的肠道疾病检测市场

  • 细菌病原体
    • 曲状桿菌
    • 大肠桿菌
    • 沙门氏菌
  • 寄生病原体
  • 病毒病原体
    • 腺病毒
    • 诺罗病毒
    • 轮状病毒

第十二章 依检体类型分類的肠道疾病检测市场

  • 血液检体
  • 直肠拭子
  • 粪便检体

13. 肠道疾病检测市场（依通路划分）

  • 直销
  • 经销商
  • 线上销售

14. 各地区肠道疾病检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肠道疾病检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国肠道疾病检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Abbott Laboratories
    • Roche Holding AG
    • QIAGEN NV
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Danaher Corporation
    • PerkinElmer, Inc.
    • DiaSorin SpA
Product Code: MRR-732E7CFCB4A5

The Enteric Disease Testing Market is projected to grow by USD 7.05 billion at a CAGR of 5.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.54 billion
Estimated Year [2025] USD 4.80 billion
Forecast Year [2032] USD 7.05 billion
CAGR (%) 5.64%

A comprehensive orientation to the evolving enteric disease testing environment where technology, regulation, and clinical needs converge to shape diagnostic strategy

Enteric disease testing sits at the intersection of clinical urgency and technological innovation, driven by the need to rapidly detect and respond to bacterial, viral, and parasitic outbreaks. Diagnostic laboratories, hospitals, research institutes, and academic centers rely on an increasingly diverse toolkit that includes biochemical testing, culture-based approaches, immunoassays, molecular diagnostics, and sequencing technologies. In parallel, evolving regulatory frameworks, changing reimbursement environments, and shifting patient pathways are reshaping how assays are validated, adopted, and integrated into routine workflows.

Today's testing ecosystem balances legacy methods such as selective and non-selective culture with modern modalities like real-time polymerase chain reaction and next-generation sequencing. This hybrid landscape requires laboratory managers and clinical leaders to evaluate trade-offs between throughput, sensitivity, turnaround time, and cost of ownership. As a result, purchasing decisions are less about replacing one technology with another and more about creating complementary diagnostic pathways that optimize patient care and surveillance capabilities.

Moreover, the proliferation of multiplex assays, rapid lateral flow formats, and data analysis software is expanding the operational footprint of enteric testing. Consequently, organizations must navigate procurement complexity, training needs, and data management challenges while preserving diagnostic quality and complying with accreditation standards. This introduction frames a marketplace where scientific rigor meets operational pragmatism, and where strategic choices will determine resilience against the next wave of enteric threats.

How technological convergence and operational modernization are redrawing diagnostic pathways and strengthening pathogen detection across clinical and public health settings

The landscape of enteric disease testing is undergoing transformative shifts driven by technological maturation, workflow consolidation, and heightened surveillance expectations. Molecular diagnostics have transitioned from niche research applications to frontline clinical tools, with polymerase chain reaction variants, loop mediated isothermal amplification, and real-time PCR enabling faster, more sensitive detection of bacterial, viral, and parasitic targets. At the same time, sequencing platforms, including next-generation and Sanger approaches, are being integrated for pathogen characterization, outbreak tracing, and antimicrobial resistance profiling, which elevates the role of data analytics and bioinformatics in routine practice.

Concurrently, immunoassays have diversified, as chemiluminescence assays, enzyme linked immunosorbent formats, and lateral flow devices expand point-of-care and laboratory-based testing options. Culture methods remain indispensable for isolate recovery and susceptibility testing, but laboratories increasingly combine culture with rapid molecular confirmation to accelerate case management. The rise of instrument automation and integrated consumable systems is reducing manual workloads, while software and maintenance services are becoming core components of procurement conversations.

These technological shifts are mirrored by operational and market dynamics. End users such as diagnostic laboratories, hospitals, research entities, and academic centers are reconfiguring workflows to accommodate multiplex testing and high-throughput sequencing. Distribution channels are adapting accordingly, with direct sales, distributors, and online platforms each playing distinct roles in meeting demand. Together, these changes are redefining how public health agencies and clinical providers detect, report, and respond to enteric threats.

Assessment of how tariff shifts in 2025 reshaped procurement practices, supply chain resilience strategies, and capital planning across diagnostic stakeholders

The introduction and adjustment of tariffs in 2025 have added a new layer of complexity to procurement and supply chain planning for enteric disease testing. Tariff adjustments affecting imported consumables, instruments, and certain laboratory components have compelled manufacturers and distributors to reassess sourcing strategies, adjust pricing models, and optimize inventory buffers to preserve continuity of testing services. These measures have had ripple effects across procurement cycles, capital expenditure planning, and the relative competitiveness of domestically produced versus imported goods.

Laboratories reliant on specialized reagents, kits, and sequencing consumables experienced pressure to identify alternative vendors or to negotiate long-term supply agreements that mitigate exposure to cost fluctuations. Instrument manufacturers responded by reengineering bills of materials, localizing certain production steps where feasible, and enhancing service offerings to justify total cost of ownership under new tariff environments. Furthermore, distributors diversified logistics routes and consolidated shipments to manage landed costs more effectively.

The tariffs also influenced the strategic calculus for end users considering capital investments. Hospitals and reference labs evaluated the trade-offs between leasing and purchasing equipment, and some accelerated procurement ahead of tariff implementations to avoid near-term cost increases. In parallel, software and maintenance services became more prominent as organizations sought to extract additional value from existing assets rather than pursue immediate hardware upgrades. Overall, the cumulative impact of tariffs has reinforced the importance of supply chain resilience, vendor diversification, and value-based procurement in sustaining enteric testing capabilities.

Deep segmentation-driven insights revealing where test method, product offerings, end-user needs, and pathogen priorities intersect to guide strategic investments

Understanding segmentation dynamics is essential to match product development and go-to-market strategies with user needs across test method, product type, end user, pathogen focus, sample type, and distribution channels. Test method considerations range from traditional biochemical tests with automated and manual approaches to culture techniques encompassing non-selective and selective media, as well as immunoassays spanning chemiluminescence, enzyme linked immunosorbent, and lateral flow formats. Molecular diagnostics present distinct value propositions through loop mediated isothermal amplification, conventional PCR, and real-time PCR platforms, while sequencing options from Sanger to next-generation sequencing support in-depth pathogen characterization and surveillance.

On the product side, consumables such as kits and reagents are core to day-to-day operations, whereas instruments including immuno analyzers, PCR machines, and sequencers represent capital investments that define throughput and capability. Complementing these are software and services, particularly data analysis tools and maintenance programs, which extend instrument uptime and translate raw outputs into actionable insights. End users span academic and clinical laboratories, diagnostic reference centers, hospitals, and research institutes, each with differing procurement cycles, regulatory requirements, and performance expectations.

Pathogen-specific segmentation underscores distinct assay design and clinical priorities: bacterial pathogens like Campylobacter, Escherichia coli, and Salmonella require both culture and molecular confirmation; viral targets such as adenovirus, norovirus, and rotavirus shift emphasis toward sensitive molecular and immunoassay detection; parasitic organisms demand specialized sample processing protocols. Sample types including blood, rectal swabs, and stool each impose upstream handling and nucleic acid extraction considerations that influence assay selection and workflow design. Finally, distribution channels-direct sales, distributors, and online platforms-shape lead times, service levels, and customer engagement models. Mapping these segments against one another reveals where integrated solutions, bundled consumable-instrument-service offerings, and targeted product enhancements can unlock clinical and operational value.

Comparative regional dynamics that drive differentiated adoption of diagnostics, influence procurement pathways, and shape supply chain resilience strategies

Regional dynamics materially influence adoption patterns, regulatory pathways, and supply chain configurations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical laboratories and hospital systems often prioritize rapid molecular diagnostics and high-throughput instruments to manage large patient volumes and support outbreak response, while regulatory approvals and reimbursement mechanisms shape the cadence of new test introductions. Laboratory networks in this region also invest in sequencing capabilities for surveillance, which drives demand for consumables and bioinformatics solutions.

Across Europe Middle East & Africa, diverse regulatory environments and heterogeneous healthcare infrastructures create differentiated opportunities for both centralized reference laboratories and decentralized testing models. In many countries, stringent validation requirements underscore the importance of certified reagents and accredited workflows, whereas public health priorities steer investment toward multiplex assays and platforms capable of integrating surveillance data. Distribution strategies must account for complex logistics across multiple jurisdictions and varying procurement practices.

The Asia-Pacific region presents a mix of highly advanced urban centers and rapidly developing laboratory markets, leading to simultaneous demand for cutting-edge sequencing and scalable immunoassay platforms. Local manufacturing hubs in some countries influence supply chain resilience and cost structures, and partnerships with regional distributors can accelerate market access. In all regions, collaborative public-private initiatives, cross-border surveillance programs, and regional procurement frameworks increasingly shape how enteric testing resources are allocated and deployed.

How market participants are differentiating through integrated offerings, strategic partnerships, and data-centric services to capture sustained clinical adoption

Major players across the enteric testing landscape are focusing on integrated solutions that combine instruments, consumables, and digital services to enhance customer retention and lifecycle value. Companies with established immunoassay and molecular portfolios are investing in automation and connectivity to reduce hands-on time and improve result reproducibility, while sequencing providers are advancing library preparation kits and streamlined bioinformatics pipelines to lower technical barriers for adoption. Smaller innovators are concentrating on niche areas such as rapid point-of-care lateral flow assays, isothermal amplification kits, or specialized media for challenging culture targets.

Strategic activity includes partnerships to expand distribution footprints, co-development agreements to accelerate assay validation, and after-sales service enhancements to improve uptime and customer satisfaction. Several firms emphasize hybrid go-to-market models that blend direct engagement with channel partnerships to address heterogeneous end-user preferences. There is also a clear trend toward subscription and service-based offerings that bundle consumables with instruments and software, thereby smoothing revenue streams and deepening customer relationships.

Competitive differentiation increasingly hinges on data capabilities, including interoperability with laboratory information systems, robust data analysis software, and services that translate complex sequencing outputs into clinically relevant intelligence. As stakeholders prioritize rapid diagnostics, scalability, and actionable insights, companies that can deliver end-to-end solutions and demonstrate measurable operational benefits will secure stronger positions in the market.

Actionable strategic moves for manufacturers and health systems to bolster resilience, accelerate adoption, and deliver measurable operational and clinical benefits

Industry leaders should act decisively to strengthen supply chains, accelerate digital integration, and align product portfolios with end-user workflow realities. First, diversifying supplier bases and establishing contingency inventory strategies will mitigate exposure to trade disruptions and tariff volatility. Second, investing in seamless data connectivity between instruments, laboratory information systems, and analytics platforms will unlock operational efficiencies and enhance the value proposition of higher-cost instrumentation.

Third, manufacturers and distributors should consider modular commercial models that combine consumables, instruments, and software services into subscription plans, which can lower barriers to entry for resource-constrained laboratories while providing predictable revenue streams. Fourth, prioritizing assay development that balances sensitivity, turnaround time, and ease of use-especially for common enteric pathogens like Campylobacter, Escherichia coli, Salmonella, norovirus, and rotavirus-will meet both clinical and public health needs. Fifth, targeted investments in training, technical support, and maintenance services will preserve uptime and improve customer satisfaction, particularly in regions with varied laboratory capabilities.

Finally, fostering collaborative relationships with academic centers, public health agencies, and hospital networks will enable co-development of surveillance-focused solutions and validation studies. By implementing these actions, industry leaders can enhance resilience, accelerate adoption of transformative diagnostics, and deliver measurable benefits across clinical and laboratory settings.

A rigorous mixed-methods research framework integrating stakeholder interviews, technical literature review, and cross-source triangulation to ensure credible insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to gather a comprehensive view of enteric disease testing dynamics. Primary engagements included structured interviews with laboratory directors, clinical microbiologists, procurement professionals, and product managers to capture real-world operational constraints, adoption drivers, and technology preferences. Supplementary discussions with distribution partners and service organizations provided context on logistics, pricing pressures, and after-sales support models.

Secondary research involved a systematic review of regulatory guidance, clinical practice standards, and recent peer-reviewed literature to ensure alignment with validated laboratory procedures and diagnostic performance expectations. Product literature, manufacturer technical specifications, and instrument service manuals were analyzed to evaluate throughput characteristics, consumable dependencies, and integration capabilities. Comparative analysis across test methods, product categories, and end-user types enabled identification of recurring themes, capability gaps, and commercialization pathways.

Data synthesis emphasized triangulation across sources to reconcile differing stakeholder perspectives and mitigate bias. Throughout the process, attention was paid to reproducibility, transparency in data sourcing, and the contextual relevance of findings to clinical laboratories, hospitals, research institutes, and academic centers. This mixed-methods approach supports robust, actionable insights while acknowledging the operational heterogeneity that characterizes enteric disease testing.

A synthesis of technological, operational, and strategic themes highlighting the path to resilient and responsive enteric diagnostics for clinical and public health needs

The enteric disease testing domain is characterized by rapid technological progress, operational complexity, and evolving market pressures that together demand strategic clarity from stakeholders. Traditional methods continue to play a vital role in pathogen recovery and resistance profiling, while molecular and sequencing technologies have become indispensable for timely detection and epidemiologic investigation. Consumables, instruments, software, and services now form an interdependent ecosystem where decisions in one area influence performance and value realization across others.

Regional nuances, tariff-driven procurement adjustments, and the need for resilient distribution strategies underscore the importance of flexible commercial models and strong after-sales capabilities. End users-from centralized reference laboratories to point-of-care settings-require tailored solutions that account for sample types, pathogen targets, and throughput needs. Companies that offer integrated, data-enabled solutions and that invest in partnerships and local support structures will be best positioned to meet these diverse requirements.

Looking ahead, the sector's trajectory will be shaped by continued innovation in assay chemistry, automation, and bioinformatics, alongside concerted efforts to build supply chain resilience and regulatory alignment. The cumulative effect will be a more responsive diagnostic infrastructure that better supports clinical decision-making and public health surveillance for enteric diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of multiplexed molecular panels for simultaneous detection of multiple enteric pathogens reducing diagnosis time
  • 5.2. Adoption of rapid point of care immunoassays for community based detection of norovirus and rotavirus infections
  • 5.3. Integration of next generation sequencing in clinical settings for comprehensive outbreak source tracking and antimicrobial resistance profiling
  • 5.4. Deployment of CRISPR based diagnostic platforms for ultra sensitive detection of low abundance enteric pathogens in stool samples
  • 5.5. Strategic partnerships between diagnostic manufacturers and telehealth providers to facilitate remote enteric disease testing and consultation
  • 5.6. Implementation of digital stool diagnostics coupled with AI analytics for predictive modeling of enteric disease outbreaks in public health surveillance
  • 5.7. Regulatory approval and commercialization of lab on a chip devices for portable multiplexed detection of bacterial viral and parasitic enteric agents
  • 5.8. Rising demand for fecal microbiome testing as a complementary tool for differential diagnosis and personalized treatment of gastrointestinal infections

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enteric Disease Testing Market, by Test Method

  • 8.1. Biochemical Tests
    • 8.1.1. Automated Biochemical Analysis
    • 8.1.2. Manual Biochemical Tests
  • 8.2. Culture Methods
    • 8.2.1. Non Selective Culture
    • 8.2.2. Selective Culture
  • 8.3. Immunoassays
    • 8.3.1. Chemiluminescence Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Assay
  • 8.4. Molecular Diagnostics
    • 8.4.1. Loop Mediated Isothermal Amplification
    • 8.4.2. Polymerase Chain Reaction
    • 8.4.3. Real Time Polymerase Chain Reaction
  • 8.5. Sequencing
    • 8.5.1. Next Generation Sequencing
    • 8.5.2. Sanger Sequencing

9. Enteric Disease Testing Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. Immuno Analyzers
    • 9.2.2. Polymerase Chain Reaction Instruments
    • 9.2.3. Sequencers
  • 9.3. Software & Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Maintenance Services

10. Enteric Disease Testing Market, by End User

  • 10.1. Academic And Clinical Laboratories
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Enteric Disease Testing Market, by Pathogen

  • 11.1. Bacterial Pathogens
    • 11.1.1. Campylobacter
    • 11.1.2. Escherichia Coli
    • 11.1.3. Salmonella
  • 11.2. Parasitic Pathogens
  • 11.3. Viral Pathogens
    • 11.3.1. Adenovirus
    • 11.3.2. Norovirus
    • 11.3.3. Rotavirus

12. Enteric Disease Testing Market, by Sample Type

  • 12.1. Blood Samples
  • 12.2. Rectal Swabs
  • 12.3. Stool Samples

13. Enteric Disease Testing Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Sales

14. Enteric Disease Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Enteric Disease Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Enteric Disease Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. bioMerieux SA
    • 17.3.3. Abbott Laboratories
    • 17.3.4. Roche Holding AG
    • 17.3.5. QIAGEN N.V.
    • 17.3.6. Becton, Dickinson and Company
    • 17.3.7. Bio-Rad Laboratories, Inc.
    • 17.3.8. Danaher Corporation
    • 17.3.9. PerkinElmer, Inc.
    • 17.3.10. DiaSorin S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ENTERIC DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ENTERIC DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENTERIC DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)

TABLE